European Oncology Nursing Society (EONS) calls for adopting new guidelines across Europe to protect nurses and
patients involved in cancer treatment.

Geneva, Switzerland – March 28th 2008: The European Oncology Nursing Society (EONS) is today calling for new guidelines to be adopted across Europe to help all nurses involved in cancer care manage extravasations, thereby improving treatment for cancer patients overall.

Extravasation is caused by the leaking of fluids used in chemotherapy from the blood vessels into surrounding tissue, which can lead to severe and permanent disabilityⁱ. It is relatively uncommon, estimated to occur in 0.1% to 1.0% of all anthracycline treatmentsⁱⁱ, however it can be debilitating,
disabling and requires immediate attention from those involved in administering intravenous chemotherapy. Over 100,000 doses of chemotherapy and a million intravenous (IV) infusions are given every day worldwideⁱⁱⁱ.

read more>>
 

To the OMX
Investor News No. 02-08 / Copenhagen, March 18, 2008

New International Diagnosis Code Created Following Savene®/TOTECT® Approvals

“We're pleased to announce that CMS has approved a new code for extravasation of vesicant chemotherapy,” said John Parsons, Chief Commercial Officer of TopoTarget. “Although vesicant extravasations are thought to occur infrequently, reliable incidence data do not exist. CMS will now be able to more accurately determine how often vesicant extravasations occur. In addition, reimbursement for extravasation treatment is contingent upon having a corresponding diagnosis. This new diagnosis code will facilitate the coding and reimbursement process.”

“We have been very pleased with the response TOTECT® has received since it was launched in the US in October 2007,” said Peter Buhl Jensen, CEO of TopoTarget.  “The establishment of an ICD-9-CM code specifically for extravasation of vesicant chemotherapy will aid in TOTECT® treatment reimbursement and help us learn more about the incidence of vesicant extravasation especially anthracycline extravasation.”

read more>>

CONTACT:

Maria Gordon Shydlo/Melanie Nadeau
Padilla Speer Beardsley
 

(212) 752-8338
FOR IMMEDIATE RELEASE

TOPOTARGET ENHANCES TOTECT® REPLACEMENT KIT POLICY
− New Six-Year Replacement Kit Policy –
− TOTECT® the Only FDA-Approved Treatment for Anthracycline Extravasation –

ROCKAWAY, N.J. (February 5, 2008) – TopoTarget USA, Inc., the U.S. subsidiary of TopoTarget A/S, a Denmark-based biotechnology firm specializing in cancer treatments, enhanced and extended its replacement kit policy to six years for TOTECT® (dexrozoxane for injection) on all kits purchased, effective immediately. TOTECT® is the only treatment approved by the U.S. Food and Drug Administration (FDA) for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding healthy tissue.

“While TOTECT® has only been available for a few months, cancer centers have already begun adopting this Orphan and patent-protected drug therapy and we have reports of successful outcomes following the use of this treatment,” said John Parsons, president of the U.S. subsidiary and global chief commercial officer. “As part of our on-going discussions with physicians, nurses and pharmacists, we have seen an opportunity to significantly extend the TOTECT® replacement kit policy, which should accelerate stocking of this emergency treatment kit.

read more>>
 

CONTACT:

Maria Gordon Shydlo/Deanna Decker

Padilla Speer Beardsley

(212) 752-8338

FOR IMMEDIATE RELEASE

TOTECT® NOW AVAILABLE FROM TOPOTARGET USA

First and Only FDA-Approved Treatment for Anthracycline Extravasation

ROCKAWAY, N.J. (October 16, 2007) – TopoTarget USA, Inc., the U.S. subsidiary of TopoTarget A/S , a Denmark-based biotechnology firm specializing in cancer treatment, announced today that TOTECT® (dexrazoxane hydrochloride for injection) is now available to cancer treatment facilities throughout the United States through its distributor ASD Healthcare and Oncology Supply, both AmeriSource Bergen companies. TOTECT® is the one and only treatment approved by the U.S. Food

and Drug Administration (FDA) for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue. The company received approval, under an orphan drug designation, from the FDA on September 6, 2007.

read more>>
 

To the OMX
Announcement No. 36-07 / Copenhagen, 16 October 2007

TopoTarget launches TOTECT® in the US

- Only FDA-Approved Treatment for Anthracycline Extravasation -

Copenhagen, Denmark – 16 October 2007 – TopoTarget A/S (OMX:TOPO) – has announced that TopoTarget USA, Inc., the US subsidiary of TopoTarget A/S , has made TOTECT® available to cancer facilities throughout the US. TOTECT® is the only FDA-approved treatment for extravasation from intravenous anthracycline chemotherapy, the accidental leakage of chemotherapy drugs into surrounding tissue.  The company received approval from the US Food and Drug Administration on 6 September 2007.

read more>>